Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Leases for 7 consecutive years, with $626000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 9.8% to $626000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $626000.0, a 9.8% decrease, with the full-year FY2024 number at $713000.0, up 239.52% from a year prior.
  • Current Leases was $626000.0 for Q3 2025 at Gyre Therapeutics, up from $622000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.0 million in Q4 2021 to a low of $100000.0 in Q1 2024.
  • A 5-year average of $933687.5 and a median of $686000.0 in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: crashed 79.34% in 2022, then skyrocketed 705.0% in 2025.
  • Gyre Therapeutics' Current Leases stood at $2.0 million in 2021, then crashed by 75.11% to $492000.0 in 2022, then plummeted by 57.32% to $210000.0 in 2023, then soared by 239.52% to $713000.0 in 2024, then dropped by 12.2% to $626000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Current Leases are $626000.0 (Q3 2025), $622000.0 (Q2 2025), and $805000.0 (Q1 2025).